Targeted 'Next-Generation' Sequencing in Anophthalmia and Microphthalmia Patients Confirms SOX2, OTX2 and FOXE3 Mutations

DSpace/Manakin Repository

Targeted 'Next-Generation' Sequencing in Anophthalmia and Microphthalmia Patients Confirms SOX2, OTX2 and FOXE3 Mutations

Citable link to this page

 

 
Title: Targeted 'Next-Generation' Sequencing in Anophthalmia and Microphthalmia Patients Confirms SOX2, OTX2 and FOXE3 Mutations
Author: Lopez Jimenez, Nelson; Yahyavi, Mani; Bardakjian, Tanya; Tonkin, Leath; Schneider, Adele; Sherr, Elliott H; Slavotinek, Anne M; Flannick, Jason A.; Li, Jiang

Note: Order does not necessarily reflect citation order of authors.

Citation: Lopez Jimenez, Nelson, Jason Flannick, Mani Yahyavi, Jiang Li, Tanya Bardakjian, Leath Tonkin, Adele Schneider, Elliott H Sherr, and Anne M Slavotinek. 2011. Targeted 'Next-Generation' Sequencing in Anophthalmia and Microphthalmia Patients Confirms SOX2, OTX2 and FOXE3 Mutations. BMC Medical Genetics 12:172.
Full Text & Related Files:
Abstract: Background: Anophthalmia/microphthalmia (A/M) is caused by mutations in several different transcription factors, but mutations in each causative gene are relatively rare, emphasizing the need for a testing approach that screens multiple genes simultaneously. We used next-generation sequencing to screen 15 A/M patients for mutations in 9 pathogenic genes to evaluate this technology for screening in A/M. Methods We used a pooled sequencing design, together with custom single nucleotide polymorphism (SNP) calling software. We verified predicted sequence alterations using Sanger sequencing. Results: We verified three mutations - c.542delC in SOX2, resulting in p.Pro181Argfs*22, p.Glu105X in OTX2 and p.Cys240X in FOXE3. We found several novel sequence alterations and SNPs that were likely to be non-pathogenic - p.Glu42Lys in CRYBA4, p.Val201Met in FOXE3 and p.Asp291Asn in VSX2. Our analysis methodology gave one false positive result comprising a mutation in PAX6 (c.1268A > T, predicting p.X423LeuextX*15) that was not verified by Sanger sequencing. We also failed to detect one 20 base pair (bp) deletion and one 3 bp duplication in SOX2. Conclusions: Our results demonstrated the power of next-generation sequencing with pooled sample groups for the rapid screening of candidate genes for A/M as we were correctly able to identify disease-causing mutations. However, next-generation sequencing was less useful for small, intragenic deletions and duplications. We did not find mutations in 10/15 patients and conclude that there is a need for further gene discovery in A/M.
Published Version: doi:10.1186/1471-2350-12-172
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262754/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10288671
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters